Clinical Trials
29 trialsSEVILLA
UNICANCER
panSOHO
Bayer
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Air Force Military Medical University, China
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
AstraZeneca
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
SHIELD
China Medical University, China
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Ligufalimab and Cadonilimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
DVDMS
Shanghai Guangsheng Biopharmaceutical Co., Ltd
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Peking Union Medical College Hospital
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Peking Union Medical College Hospital
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PILOT-BTC
Peking Union Medical College Hospital
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
Tongji Hospital
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
University of Pittsburgh
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
SAIB
First Affiliated Hospital of Zhejiang University
A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors.
Shanghai Zhongshan Hospital
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
OPTIMUM
Asan Medical Center
Adebrelimab With or Without SHR-8068 in Combination With Cisplatin Plus Gemcitabine as First-line Treatment in Patients With Advanced Biliary Tract Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University